Edesa Biotech Valuation
| EDSA Stock | USD 2.30 0.09 4.07% |
Based on Macroaxis valuation methodology, the firm appears to be undervalued. Edesa Biotech shows a prevailing Real Value of $14.8 per share. The current price of the firm is $2.3. Our model computes the value of Edesa Biotech from reviewing the firm fundamentals such as Shares Owned By Insiders of 33.02 %, shares owned by institutions of 12.19 %, and Current Valuation of 5.47 M as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Edesa Biotech's valuation include:
Price Book 2.6051 | Enterprise Value 5.5 M | Enterprise Value Ebitda (1.25) | Price Sales 120.5 K | Forward PE 0.1716 |
Undervalued
Today
Please note that Edesa Biotech's price fluctuation is somewhat reliable at this time. Calculation of the real value of Edesa Biotech is based on 3 months time horizon. Increasing Edesa Biotech's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Edesa Biotech is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Edesa Stock. However, Edesa Biotech's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.3 | Real 14.8 | Target 52.33 | Hype 2.33 | Naive 2.52 |
The real value of Edesa Stock, also known as its intrinsic value, is the underlying worth of Edesa Biotech Company, which is reflected in its stock price. It is based on Edesa Biotech's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Edesa Biotech's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Edesa Biotech helps investors to forecast how Edesa stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Edesa Biotech more accurately as focusing exclusively on Edesa Biotech's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Edesa Biotech's intrinsic value based on its ongoing forecasts of Edesa Biotech's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Edesa Biotech's closest peers. If more than one evaluation category is relevant for Edesa Biotech we suggest using both methods to arrive at a better estimate.
Edesa Biotech Cash |
|
Edesa Valuation Trend
Comparing Edesa Biotech's enterprise value against its market capitalization is a good way to estimate the value of Edesa Biotech uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Edesa Biotech Total Value Analysis
Edesa Biotech is currently projected to have valuation of 5.47 M with market capitalization of 7.47 M, debt of 94.49 K, and cash on hands of 12.81 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Edesa Biotech fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
5.47 M | 7.47 M | 94.49 K | 12.81 M |
Edesa Biotech Asset Utilization
One of the ways to look at asset utilization of Edesa is to check how much profit was generated for every dollar of assets it reports. Edesa Biotech shows a negative utilization of assets of -0.72 percent, losing $0.007152 for each dollar of assets held by the firm. Inadequate asset utilization denotes the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Edesa Biotech shows how discouraging it operates for each dollar spent on its assets.Edesa Biotech Ownership Allocation
Edesa Biotech retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares.Edesa Biotech Profitability Analysis
Net Loss for the year was (8.37 M) with profit before overhead, payroll, taxes, and interest of 311.2 K.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Edesa Biotech's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Edesa Biotech and how it compares across the competition.
About Edesa Biotech Valuation
The stock valuation mechanism determines Edesa Biotech's current worth on a weekly basis. Our valuation model uses a comparative analysis of Edesa Biotech. We calculate exposure to Edesa Biotech's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Edesa Biotech's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -165.1 K | -156.9 K | |
| Pretax Profit Margin | (26.00) | (27.30) | |
| Operating Profit Margin | (17.67) | (18.56) | |
| Net Loss | (26.08) | (27.38) | |
| Gross Profit Margin | (0.94) | (0.89) |
Edesa Biotech Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 2.9 M | |
| Forward Price Earnings | 0.1716 |
Edesa Biotech Current Valuation Indicators
Valuation refers to the process of determining the present value of Edesa Biotech and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Edesa we look at many different elements of the entity such as Edesa's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Edesa Biotech, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Edesa Biotech's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Edesa Biotech's worth.Complementary Tools for Edesa Stock analysis
When running Edesa Biotech's price analysis, check to measure Edesa Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edesa Biotech is operating at the current time. Most of Edesa Biotech's value examination focuses on studying past and present price action to predict the probability of Edesa Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edesa Biotech's price. Additionally, you may evaluate how the addition of Edesa Biotech to your portfolios can decrease your overall portfolio volatility.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |